Recent press releases

June 23, 2017

FDA Approves HAEGARDA® KING OF PRUSSIA, Pa.– June 23, 2017

June 22, 2017

FDA approves first subcutaneous C1 Esterase Inhibitor to treat rare genetic disease

May 24, 2017

Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop

May 24, 2017

Shire’s Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

WHO WE ARE

The US HAEA is a non-profit patient advocacy organization dedicated to serving persons with angioedema.
We provide patients and families with a support network and wide range of services.

WE ARE
  • PATIENTS
  • CAREGIVERS
  • UNBIASED
  • RELIABLE
  • HERE FOR YOU
  • HAE.

Press contact


Janet Long
Executive Vice President
Contact Janet Long

HAEA on social media

                  

Post your HAE related content with our shared tags
#haea
#wearehae
#raredisease

Download

 

Jump to our sections with comprehensive content and learn more

null

What is HAE

Get to know the disease: symptoms, diagnose, treatments and more

Take me there >

Professionals

For healthcare providers. Knowledge, CME-programs and more

Take me there >

Living with HAE

Care takers and givers: HAE will affect your life - But you can still be in control.

Take me there >

Resources

Our area with a lot of usefull information

Take me there >